1 Zumla, A. & Hui, D. S. C. Emerging and Reemerging Infectious Diseases: Global Overview. Infect Dis Clin North Am 33, xiii-xix, doi:10.1016/j.idc.2019.09.001 (2019).
2 Lucchese, G. Epitopes for a 2019-nCoV vaccine. Cell Mol Immunol, doi:10.1038/s41423-020-0377-z (2020).
3 Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, doi:10.1001/jama.2020.1585 (2020).
4 Coronaviridae Study Group of the International Committee on Taxonomy of, V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, doi:10.1038/s41564-020-0695-z (2020).
5 Maslow, J. N. The cost and challenge of vaccine development for emerging and emergent infectious diseases. Lancet Glob Health 6, e1266-e1267, doi:10.1016/S2214-109X(18)30418-2 (2018).
6 Oh, S. J., Choi, Y. K. & Shin, O. S. Systems Biology-Based Platforms to Accelerate Research of Emerging Infectious Diseases. Yonsei Med J 59, 176-186, doi:10.3349/ymj.2018.59.2.176 (2018).
7 Shahid, F., Ashfaq, U. A., Javaid, A. & Khalid, H. Immunoinformatics guided rational design of a next generation multi epitope based peptide (MEBP) vaccine by exploring Zika virus proteome. Infect Genet Evol 80, 104199, doi:10.1016/j.meegid.2020.104199 (2020).
8 Pandey, R. K., Bhatt, T. K. & Prajapati, V. K. Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein. Sci Rep 8, 1125, doi:10.1038/s41598-018-19456-1 (2018).
9 Raeven, R. H. M., van Riet, E., Meiring, H. D., Metz, B. & Kersten, G. F. A. Systems vaccinology and big data in the vaccine development chain. Immunology 156, 33-46, doi:10.1111/imm.13012 (2019).
10 Parvizpour, S., Pourseif, M. M., Razmara, J., Rafi, M. A. & Omidi, Y. Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discovery Today, doi:https://doi.org/10.1016/j.drudis.2020.03.006 (2020).
11 Barzegari, A., Saeedi, N., Zarredar, H., Barar, J. & Omidi, Y. The search for a promising cell factory system for production of edible vaccine. Hum Vaccin Immunother 10, 2497-2502, doi:10.4161/hv.29032 (2014).
12 Pourseif, M. M. et al. Current status and future prospective of vaccine development against Echinococcus granulosus. Biologicals 51, 1-11, doi:10.1016/j.biologicals.2017.10.003 (2018).
13 Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther 27, 757-772, doi:10.1016/j.ymthe.2019.01.020 (2019).
14 McPherson, C. et al. Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant. Methods Mol Biol 1403, 269-284, doi:10.1007/978-1-4939-3387-7_14 (2016).
15 Ng, O. W. & Tan, Y. J. Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks - Implications for coronavirus vaccine development. Hum Vaccin Immunother 13, 186-189, doi:10.1080/21645515.2016.1228500 (2017).
16 Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol 35, 1547-1549, doi:10.1093/molbev/msy096 (2018).
17 Pourseif, M. M., Yousefpour, M., Aminianfar, M., Moghaddam, G. & Nematollahi, A. A multi-method and structure-based in silico vaccine designing against Echinococcus granulosus through investigating enolase protein. Bioimpacts 9, 131-144, doi:10.15171/bi.2019.18 (2019).
18 Guo, J. P., Petric, M., Campbell, W. & McGeer, P. L. SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology 324, 251-256, doi:10.1016/j.virol.2004.04.017 (2004).
19 Yang, Z. et al. UCSF Chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol 179, 269-278, doi:10.1016/j.jsb.2011.09.006 (2012).
20 Peters, B. et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol 2, e65, doi:10.1371/journal.pcbi.0020065 (2006).
21 Zhang, Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 40, doi:10.1186/1471-2105-9-40 (2008).
22 Zhang, Y. & Skolnick, J. Scoring function for automated assessment of protein structure template quality. Proteins 57, 702-710, doi:10.1002/prot.20264 (2004).
23 Kozakov, D. et al. The ClusPro web server for protein-protein docking. Nat Protoc 12, 255-278, doi:10.1038/nprot.2016.169 (2017).
24 Wang, W. et al. Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res 128, 1-8, doi:10.1016/j.virusres.2007.02.007 (2007).
25 Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51, 2778-2786, doi:10.1021/ci200227u (2011).
26 Chen, N. et al. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69, 297-304, doi:10.1002/iub.1625 (2017).
27 Grifoni, A. et al. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe, doi:10.1016/j.chom.2020.03.002 (2020).
28 Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 12, doi:10.3390/v12030254 (2020).
29 Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol, doi:10.1038/s41423-020-0400-4 (2020).
30 Tarang, S. et al. In silico Design of a Multivalent Vaccine Against Candida albicans. Sci Rep 10, 1066, doi:10.1038/s41598-020-57906-x (2020).
31 Robson, B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Comput Biol Med 119, 103670, doi:10.1016/j.compbiomed.2020.103670 (2020).
32 Moxon, R., Reche, P. A. & Rappuoli, R. Editorial: Reverse Vaccinology. Front Immunol 10, 2776, doi:10.3389/fimmu.2019.02776 (2019).
33 Sanchez-Trincado, J. L., Gomez-Perosanz, M. & Reche, P. A. Fundamentals and Methods for T- and B-Cell Epitope Prediction. J Immunol Res 2017, 2680160, doi:10.1155/2017/2680160 (2017).
34 Pourseif, M. M., Moghaddam, G., Daghighkia, H., Nematollahi, A. & Omidi, Y. A novel B- and helper T-cell epitopes-based prophylactic vaccine against Echinococcus granulosus. Bioimpacts 8, 39-52, doi:10.15171/bi.2018.06 (2018).
35 Solanki, V., Tiwari, M. & Tiwari, V. Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa. Sci Rep 9, 5240, doi:10.1038/s41598-019-41496-4 (2019).
36 Shey, R. A. et al. In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases. Sci Rep 9, 4409, doi:10.1038/s41598-019-40833-x (2019).
37 Pourseif, M. M. et al. A novel in silico minigene vaccine based on CD4(+) T-helper and B-cell epitopes of EG95 isolates for vaccination against cystic echinococcosis. Comput Biol Chem 72, 150-163, doi:10.1016/j.compbiolchem.2017.11.008 (2018).
38 Yi, H. 2019 novel coronavirus is undergoing active recombination. Clin Infect Dis, doi:10.1093/cid/ciaa219 (2020).
39 Kristian G. Andersen, A. R., W. Ian Lipkin, Edward C. Holmes and Robert F. Garry The proximal origin of SARS-CoV-2. Nature Medicine, doi:https://doi.org/10.1038/s41591-020-0820-9 (2020).
40 Ning, T. et al. Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization. J Infect Dis 216, 867-876, doi:10.1093/infdis/jix274 (2017).
41 Zhang, T., Wu, Q. & Zhang, Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr Biol 30, 1346-1351 e1342, doi:10.1016/j.cub.2020.03.022 (2020).
42 Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, doi:10.1016/j.cell.2020.02.058 (2020).
43 Arunachalam Ramaiah, V. A. Insights into Cross-species Evolution of Novel Human Coronavirus 2019-nCoV and Defining Immune Determinants for Vaccine Development. bioRxiv 925867, doi:https://doi.org/10.1101/2020.01.29.925867 (2020).
44 Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of antigen processing. Annu Rev Immunol 31, 443-473, doi:10.1146/annurev-immunol-032712-095910 (2013).
45 Trolle, T. et al. The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. J Immunol 196, 1480-1487, doi:10.4049/jimmunol.1501721 (2016).
46 Tian, Y., Grifoni, A., Sette, A. & Weiskopf, D. Human T Cell Response to Dengue Virus Infection. Front Immunol 10, 2125, doi:10.3389/fimmu.2019.02125 (2019).
47 Sette, A. et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28, 847-858, doi:10.1016/j.immuni.2008.04.018 (2008).
48 Burrows, S. R., Rossjohn, J. & McCluskey, J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol 27, 11-16, doi:10.1016/j.it.2005.11.001 (2006).
49 Samino, Y. et al. A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural ligands from HIV envelope protein. J Biol Chem 281, 6358-6365, doi:10.1074/jbc.M512263200 (2006).
50 Li, M., Jiang, Y., Gong, T., Zhang, Z. & Sun, X. Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant. Mol Pharm 13, 885-894, doi:10.1021/acs.molpharmaceut.5b00802 (2016).
51 Hajam, I. A., Dar, P. A., Shahnawaz, I., Jaume, J. C. & Lee, J. H. Bacterial flagellin-a potent immunomodulatory agent. Exp Mol Med 49, e373, doi:10.1038/emm.2017.172 (2017).
52 Kim, E. et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine, 102743, doi:10.1016/j.ebiom.2020.102743 (2020).
53 Hussain, S. et al. TLR5 participates in the TLR4 receptor complex and promotes MyD88-dependent signaling in environmental lung injury. Elife 9, doi:10.7554/eLife.50458 (2020).
54 Versteeg, L., Almutairi, M. M., Hotez, P. J. & Pollet, J. Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections. Vaccines (Basel) 7, doi:10.3390/vaccines7040122 (2019).
55 Alexander, J. et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 164, 1625-1633, doi:10.4049/jimmunol.164.3.1625 (2000).
56 Dehghani, J. et al. Stable transformation of Spirulina (Arthrospira) platensis: a promising microalga for production of edible vaccines. Appl Microbiol Biotechnol 102, 9267-9278, doi:10.1007/s00253-018-9296-7 (2018).
57 Dehghani, J. et al. Towards a new avenue for producing therapeutic proteins: Microalgae as a tempting green biofactory. Biotechnol Adv 40, 107499, doi:10.1016/j.biotechadv.2019.107499 (2020).
58 Zhang, C., Maruggi, G., Shan, H. & Li, J. Advances in mRNA Vaccines for Infectious Diseases. Front Immunol 10, 594, doi:10.3389/fimmu.2019.00594 (2019).
59 Daryabari, S. S. et al. Overexpression of CFL1 in gastric cancer and the effects of its silencing by siRNA with a nanoparticle delivery system in the gastric cancer cell line. J Cell Physiol, doi:10.1002/jcp.29562 (2020).
60 Jafari, B., Pourseif, M. M., Barar, J., Rafi, M. A. & Omidi, Y. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opin Drug Deliv 16, 583-605, doi:10.1080/17425247.2019.1614911 (2019).
61 Lundstrom, K. Self-Replicating RNA Viruses for RNA Therapeutics. Molecules 23, doi:10.3390/molecules23123310 (2018).
62 Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32, 1792-1797, doi:10.1093/nar/gkh340 (2004).
63 Jones, D. T., Taylor, W. R. & Thornton, J. M. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 8, 275-282, doi:10.1093/bioinformatics/8.3.275 (1992).
64 Dopazo, J. Estimating errors and confidence intervals for branch lengths in phylogenetic trees by a bootstrap approach. J Mol Evol 38, 300-304, doi:10.1007/bf00176092 (1994).
65 Tsirigos, K. D., Peters, C., Shu, N., Kall, L. & Elofsson, A. The TOPCONS web server for consensus prediction of membrane protein topology and signal peptides. Nucleic Acids Res 43, W401-407, doi:10.1093/nar/gkv485 (2015).
66 Dobson, L., Remenyi, I. & Tusnady, G. E. CCTOP: a Consensus Constrained TOPology prediction web server. Nucleic Acids Res 43, W408-412, doi:10.1093/nar/gkv451 (2015).
67 Chen, Y., Yu, P., Luo, J. & Jiang, Y. Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT. Mamm Genome 14, 859-865, doi:10.1007/s00335-003-2296-6 (2003).
68 Marchler-Bauer, A. et al. CDD/SPARCLE: functional classification of proteins via subfamily domain architectures. Nucleic Acids Res 45, D200-D203, doi:10.1093/nar/gkw1129 (2017).
69 Hall, T. A. BioEdit: A User-Friendly Biological Sequence Alignment Editor and Analysis Program for Windows 95/98/NT. Nucleic Acids Symposium Series 41, 95-98 (1999).
70 Buchan, D. W. A. & Jones, D. T. The PSIPRED Protein Analysis Workbench: 20 years on. Nucleic Acids Res 47, W402-W407, doi:10.1093/nar/gkz297 (2019).
71 Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46, W296-W303, doi:10.1093/nar/gky427 (2018).
72 Heo, L., Park, H. & Seok, C. GalaxyRefine: Protein structure refinement driven by side-chain repacking. Nucleic Acids Res 41, W384-388, doi:10.1093/nar/gkt458 (2013).
73 Pronk, S. et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29, 845-854, doi:10.1093/bioinformatics/btt055 (2013).
74 Parvizpour, S., Razmara, J., Pourseif, M. M. & Omidi, Y. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. Bioimpacts 9, 45-56, doi:10.15171/bi.2019.06 (2019).
75 Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8, 477-486, doi:10.1007/bf00228148 (1996).
76 Eisenberg, D., Luthy, R. & Bowie, J. U. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 277, 396-404, doi:10.1016/s0076-6879(97)77022-8 (1997).
77 Colovos, C. & Yeates, T. O. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 2, 1511-1519, doi:10.1002/pro.5560020916 (1993).
78 Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 45, W24-W29, doi:10.1093/nar/gkx346 (2017).
79 Singh, H., Ansari, H. R. & Raghava, G. P. Improved method for linear B-cell epitope prediction using antigen's primary sequence. PLoS One 8, e62216, doi:10.1371/journal.pone.0062216 (2013).
80 Gupta, S., Ansari, H. R., Gautam, A., Open Source Drug Discovery, C. & Raghava, G. P. Identification of B-cell epitopes in an antigen for inducing specific class of antibodies. Biol Direct 8, 27, doi:10.1186/1745-6150-8-27 (2013).
81 Ansari, H. R. & Raghava, G. P. Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res 6, 6, doi:10.1186/1745-7580-6-6 (2010).
82 Odorico, M. & Pellequer, J. L. BEPITOPE: predicting the location of continuous epitopes and patterns in proteins. J Mol Recognit 16, 20-22, doi:10.1002/jmr.602 (2003).
83 Saha, S. & Raghava, G. P. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 65, 40-48, doi:10.1002/prot.21078 (2006).
84 Zhou, C. et al. SEPPA 3.0-enhanced spatial epitope prediction enabling glycoprotein antigens. Nucleic Acids Res 47, W388-W394, doi:10.1093/nar/gkz413 (2019).
85 Kringelum, J. V., Lundegaard, C., Lund, O. & Nielsen, M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol 8, e1002829, doi:10.1371/journal.pcbi.1002829 (2012).
86 Ponomarenko, J. et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 9, 514, doi:10.1186/1471-2105-9-514 (2008).
87 Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7, 539, doi:10.1038/msb.2011.75 (2011).
88 Pickett, B. E. et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res 40, D593-598, doi:10.1093/nar/gkr859 (2012).
89 Moutaftsi, M. et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 24, 817-819, doi:10.1038/nbt1215 (2006).
90 Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12, 1007-1017, doi:10.1110/ps.0239403 (2003).
91 Wang, P. et al. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4, e1000048, doi:10.1371/journal.pcbi.1000048 (2008).
92 Greenbaum, J. et al. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 63, 325-335, doi:10.1007/s00251-011-0513-0 (2011).
93 Gonzalez-Galarza, F. F. et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 43, D784-788, doi:10.1093/nar/gku1166 (2015).
94 Vita, R. et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res 47, D339-D343, doi:10.1093/nar/gky1006 (2019).
95 Patel, M. C. et al. Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol 9, 811-829, doi:10.2217/fvl.14.70 (2014).
96 Shah, M., Anwar, M. A., Kim, J. H. & Choi, S. Advances in Antiviral Therapies Targeting Toll-like Receptors. Expert Opin Investig Drugs 25, 437-453, doi:10.1517/13543784.2016.1154040 (2016).
97 Shanmugam, A. et al. Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants. PLoS One 7, e30839, doi:10.1371/journal.pone.0030839 (2012).
98 Skountzou, I. et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28, 4103-4112, doi:10.1016/j.vaccine.2009.07.058 (2010).
99 Kridel, S. J. et al. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem 276, 20572-20578, doi:10.1074/jbc.M100900200 (2001).
100 Varani, J. et al. Collagenolytic and gelatinolytic matrix metalloproteinases and their inhibitors in basal cell carcinoma of skin: comparison with normal skin. Br J Cancer 82, 657-665, doi:10.1054/bjoc.1999.0978 (2000).
101 Schonefuss, A. et al. Upregulation of cathepsin S in psoriatic keratinocytes. Exp Dermatol 19, e80-88, doi:10.1111/j.1600-0625.2009.00990.x (2010).
102 Riese, R. J. et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 101, 2351-2363, doi:10.1172/JCI1158 (1998).
103 Lucke, M. et al. Engineered hybrid spider silk particles as delivery system for peptide vaccines. Biomaterials 172, 105-115, doi:10.1016/j.biomaterials.2018.04.008 (2018).
104 Tews, B. A. & Meyers, G. Self-Replicating RNA. Methods Mol Biol 1499, 15-35, doi:10.1007/978-1-4939-6481-9_2 (2017).
105 Zeng, C. et al. Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo. bioRxiv, 2020.2004.2001.019877, doi:10.1101/2020.04.01.019877 (2020).
106 Zaharieva, N., Dimitrov, I., Flower, D. R. & Doytchinova, I. VaxiJen Dataset of Bacterial Immunogens: An Update. Curr Comput Aided Drug Des 15, 398-400, doi:10.2174/1573409915666190318121838 (2019).
107 Saha, S. & Raghava, G. P. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res 34, W202-209, doi:10.1093/nar/gkl343 (2006).
108 Dimitrov, I., Bangov, I., Flower, D. R. & Doytchinova, I. AllerTOP v.2--a server for in silico prediction of allergens. J Mol Model 20, 2278, doi:10.1007/s00894-014-2278-5 (2014).
109 Wilkins, M. R. et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112, 531-552, doi:10.1385/1-59259-584-7:531 (1999).
110 Garnier, J., Gibrat, J. F. & Robson, B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol 266, 540-553, doi:10.1016/s0076-6879(96)66034-0 (1996).
111 Yang, J. & Zhang, Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res 43, W174-181, doi:10.1093/nar/gkv342 (2015).
112 Pettersen, E. F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25, 1605-1612, doi:10.1002/jcc.20084 (2004).